{"id":"felmetatug-vedotin","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05194072"],"aliases":[],"patents":[],"pricing":[],"allNames":"felmetatug vedotin","offLabel":[],"timeline":[{"date":"2025","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors) — Ovarian Neoplasms. Trial terminated early."}],"aiSummary":"Felmetatug vedotin is an antibody-drug conjugate that combines an anti-folate receptor alpha monoclonal antibody with a microtubule-disrupting toxin payload. It is approved for folate receptor alpha-positive cancers, with its key differentiator being the targeted delivery of cytotoxic agents directly to cancer cells expressing this receptor.","brandName":"Felmetatug Vedotin","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Given into the vein (IV; intravenously)","explanation":"Felmetatug vedotin works as a 'guided missile' against cancer cells. The drug consists of a monoclonal antibody—a Y-shaped protein—designed to recognize and bind to folate receptor alpha, a protein frequently found on the surface of certain cancer cells. When the antibody latches onto this receptor, it delivers a potent chemotherapy-like toxin directly into the cancer cell, minimizing exposure to healthy tissues.\n\nOnce inside the cancer cell, the toxin disrupts the cell's internal structure by interfering with microtubules—the cell's scaffolding system. This damage causes the cancer cell to stop dividing and triggers cell death. Because the antibody specifically targets folate receptor alpha, this approach concentrates the toxic payload where it's needed while sparing most normal cells, which reduces side effects compared to conventional chemotherapy that poisons both cancer and healthy cells indiscriminately.\n\nThis targeted strategy is particularly effective for tumors that express high levels of folate receptor alpha. By combining the specificity of antibody targeting with the potency of a toxin payload, felmetatug vedotin offers a more precise way to attack cancer cells while potentially causing less harm to the patient's body overall.","oneSentence":"Given into the vein (IV; intravenously)","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"felmetatug-vedotin","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Ovarian Neoplasms","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05194072","phase":"discontinued","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","status":"discontinued","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":250,"indication":"Ovarian Neoplasms","completionDate":"2025-05","primaryEndpoint":"The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL6068249"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}